Goldman Sachs’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Goldman Sachs’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-356	Closed	-$5.12K	–	6320
2022 Q4	$5.12K	Buy	+356	New	+$6.87K	﹤0.01%	5812
2022 Q1	–	Sell	-616	Closed	-$28K	–	6989
2021 Q4	$28K	Sell	616 -115	-16%	-$6.89K	﹤0.01%	6333
2021 Q3	$52K	Sell	731 -9,575	-93%	-$1.09M	﹤0.01%	6039
2021 Q2	$1.36M	Buy	10,306 +119	+1%	+$14.9K	﹤0.01%	4534
2021 Q1	$1.36M	Buy	+10,187	New	+$1.29M	﹤0.01%	4362

Other funds holding ASLN

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Waterfront Wealth Overland Park, Kansas $545M AUM 19.05% 1-Year Est. Return

Goldman Sachs's ASLN Position: Q1 2023 in Review

Goldman Sachs sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q1 2023, closing a stake of 356 shares — an estimated $5.12K sold.

Goldman Sachs first reported a position in ASLN in Q1 2021 and held it in 5 quarters. The position peaked at $1.36M in Q1 2021. 16 funds tracked by Wall St. Rank hold ASLN as of Q1 2023.

Goldman Sachs reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 356 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q1 2023, an estimated $5.12K.
Goldman Sachs first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q1 2021 and held it in 5 quarters.
Goldman Sachs's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $1.36M in Q1 2021.
16 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.